Silence Therapeutics Corp (SLN): Company Short-Term Debt

Official company branding of Silence Therapeutics (SLN)

Silence Therapeutics (SLN) specializes in developing advanced medical drugs and genetics-based diagnostic systems. The price action reflects the current 0.00 indicator. The firm's environmental policy focuses on purifying laboratory emissions and reducing toxins. Meanwhile, the operating model relies on engaging external research organizations, which are managed by the company's leadership.

SLN (Silence Therapeutics plc) Short-Term Debt history from 06/21/2023 to 10/31/2026

SLN (Silence Therapeutics Corp): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Silence Therapeutics plc|SLN - Analyst Median Target
- stock exchange capitalization data:
Market Value Silence Therapeutics plc|SLN - Total Company Value
- shareholders' equity book value data:
Book Value per Share Silence Therapeutics|SLN - Total Stockholders' Equity|Market Value to Book Value Ratio silence-therapeutics.com|SLN - Total Business Assets
- company total debt and liquidity indicators:
Total Debt to Capital Silence Therapeutics|SLN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Silence Therapeutics|SLN - Company Cumulative Debt|Debt to Book Value Silence Therapeutics plc|SLN - Company Long-Term Loans and Borrowings|Company Current Liabilities Silence Therapeutics|Quick Ratio silence-therapeutics.com
- net income and valuation multiples indicators:
SLN - Final Profit
Basic company analysis:Silence Therapeutics plc - SLN
Manufactured products of Silence Therapeutics Corp

The business model of Silence Therapeutics (SLN) is based on licensing revenues from the development of RNA drugs for the treatment of cardiovascular pathologies. By analyzing short-term debt dynamics, an investor assesses the volume of obligations with a maturity of up to twelve months. This metric measures the risk of a liquidity gap by comparing current debts with available liquidity. Low values confirm financial stability, although excessive caution may hinder the scaling of R&D. Market consensus views this indicator as a safeguard against bankruptcy.

Competing companies

Tempus AI, Inc - Company Short-Term Debts|Short-Term Debt Volume Qiagen NV QGEN|Ionis Pharma (IONS) - Company Short-Term Debt|RGEN (Repligen Inc.) - Company Short-Term Debt|RNA (Avidity Biosciences) - Company Short-Term Debts|Short-Term Debt crisprtx.com CRSP|Company Short-Term Debt GeneDx (WGS)|Ultragenyx Pharmaceutical Inc. - Company Short-Term Indebtedness|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|SRPT - Company Current Liabilities|Twist Bioscience - Company Short-Term Debts|Short-Term Debt 10xgenomics.com|NTLA (Intellia Therapeutics, Inc.) - Company Current Liabilities|Stoke Therapeutics Inc - Company Short-Term Loans and Borrowings|Company Current Liabilities BLFS|WVE (Wave Pharma) - Amount of Current Liabilities|Company Short-Term Debts MAZE|SION (sionnatx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts PRME (Prime Medicine)|Taysha Gene Therapies Inc (TSHA) - Short-Term Debt|QURE - Company Short-Term Debt|Company Short-Term Loans and Borrowings MGTX (MeiraGTx Corp)|RGNX: Company Short-Term Debts|solidbio.com (SLDB) - Company Short-Term Debts|Company Short-Term Debt Ocugen|Pacific Biosciences of California, Inc. - Current Liabilities|Company Short-Term Debts BNTC|DSGN - Short-Term Debt|Rocket Pharmaceuticals - Company Current Liabilities|Company Short-Term Debts 4dmoleculartherapeutics.com FDMT|LXEO: Company Current Liabilities|Korro Bio, Inc. - Amount of Current Liabilities|EDIT: Company Short-Term Debts|PRQR - Short-Term Debt Volume|CDXS (Codexis Inc) - Company Short-Term Debts|Company Current Liabilities sangamo.com (SGMO)|Company Short-Term Debt Nautilus Biotechnology (NAUT)|Short-Term Debt Volume Metagenomi Inc.|Company Short-Term Debt Precision BioSciences DTIL|Short-Term Debt Volume Generation Bio Co (GBIO)|BOLD - Company Short-Term Debt|XCUR: Company Short-Term Debt|imunon.com (IMNN) - Company Short-Term Debt|Company Short-Term Indebtedness PHIO|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Short-Term Indebtedness RNAZ (TransCode)|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|adnas.com - Company Short-Term Indebtedness|Company Short-Term Debts BLUE (bluebird bio)|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|OMGA - Company Short-Term Debt|Short-Term Debt Volume Singular Genomics Corp OMIC|RGLS: Company Short-Term Debts|SYRS - Short-Term Debt Volume|Company Short-Term Debt Telesis Bio|Company Short-Term Debt TCON|Company Short-Term Debts UBX